Market Place
Sourcing Support
Theravance Biopharma to Attend Upcoming Investor Conference
20 Nov 2024 //
PR NEWSWIRE
Theravance Bio Reports Q3 2024 Results & Shareholder Initiatives
12 Nov 2024 //
PR NEWSWIRE
Theravance Bio To Report Q3 2024 Financial Results On Nov 12
24 Oct 2024 //
PR NEWSWIRE
Theravance Publishes YUPELRI® Spirometry Analysis In Journal
18 Oct 2024 //
PR NEWSWIRE
Theravance Biopharma to Participate in an Upcoming Investor Conference
27 Aug 2024 //
PR NEWSWIRE
Theravance Biopharma Reports Q2 2024 Results And Business Update
05 Aug 2024 //
PR NEWSWIRE
Theravance Biopharma to Participate in an Upcoming Investor Conference
25 Jul 2024 //
PR NEWSWIRE
Theravance Biopharma Reports Q1 2024 Results, Business Update
13 May 2024 //
PR NEWSWIRE
Theravance Biopharma Q1 2024 Results on May 13
29 Apr 2024 //
PR NEWSWIRE
Theravance Biopharma Hosts Virtual KOL Event on Ampreloxetine
10 Apr 2024 //
PR NEWSWIRE
Theravance Reports Fourth Quarter and Full Year 2023 Financial Results
26 Feb 2024 //
PR NEWSWIRE
Theravance to Report Fourth Quarter and Full Year 2023 Financial Results
14 Feb 2024 //
PR NEWSWIRE
Theravance Biopharma Announces Results from the Phase 4 YUPELRI® PIFR-2 Study
05 Jan 2024 //
PR NEWSWIRE
Theravance`s COPD med Yupelri flunks head-to-head study
05 Jan 2024 //
FIERCE PHARMA
Theravance Biopharma to Present New Ampreloxetine Data
16 Nov 2023 //
PR NEWSWIRE
Theravance to Participate in the 6th Annual Evercore ISI HealthCONx Conference
15 Nov 2023 //
PR NEWSWIRE
Viatris and Theravance Biopharma Announce Positive Top-Line Results from YUPELRI
13 Nov 2023 //
PR NEWSWIRE
Theravance Biopharma, Inc. Reports Third Quarter 2023 Financial Results
07 Nov 2023 //
PR NEWSWIRE
Theravance to Report Third Quarter 2023 Financial Results on November 7, 2023
19 Oct 2023 //
PR NEWSWIRE
Theravance Biopharma to Participate in an Upcoming Investor Conference
29 Aug 2023 //
PR NEWSWIRE
Theravance Biopharma to Present New Ampreloxetine Data at the 2023
28 Aug 2023 //
PR NEWSWIRE
Theravance to Report Second Quarter 2023 Financial Results on August 7, 2023
24 Jul 2023 //
PR NEWSWIRE
Theravance Biopharma Announces Orphan Drug Designation Granted to Ampreloxetine
09 May 2023 //
PR NEWSWIRE
Theravance Bio to Report First Quarter 2023 Financial Results on May 8, 2023
24 Apr 2023 //
PR NEWSWIRE
Theravance Biopharma to Participate in an Upcoming Investor Conference
10 Apr 2023 //
PR NEWSWIRE
Theravance Biopharma to Participate in an Upcoming Investor Conference
02 Mar 2023 //
PR NEWSWIRE
Theravance cuts 17% of staff, JAK inhibitor program
01 Mar 2023 //
ENDPTS
Theravance Reports Fourth Quarter / Full Year 2022 Financial Results
27 Feb 2023 //
PR NEWSWIRE
Activist investor pushes for management overhaul, strategic review at Theravance
27 Feb 2023 //
ENDPTS
Theravance to Report Fourth Quarter and Full Year 2022 Financial Results
21 Feb 2023 //
PR NEWSWIRE
Theravance Biopharma to Participate in an Upcoming Investor Conference
09 Feb 2023 //
PR NEWSWIRE
Theravance Biopharma, Inc. Highlights 2022 Accomplishments and 2023 Key Targets
09 Jan 2023 //
PR NEWSWIRE
Theravance Biopharma, Inc. Announces Final Results of Tender Offer
22 Nov 2022 //
PRNEWSWIRE
Ampreloxetine Data in Neurogenic Orthostatic Hypotension to be Presented
02 Nov 2022 //
PRNEWSWIRE
Theravance Biopharma to Report Third Quarter 2022 Financial Results
31 Oct 2022 //
PRNEWSWIRE
Theravance Biopharma to Present New Ampreloxetine Data at Symposium
25 Oct 2022 //
PRNEWSWIRE
Theravance Biopharma, Inc. Initiates $250 Million Capital Return Program
20 Sep 2022 //
PRNEWSWIRE
Theravance Biopharma Reports Second Quarter 2022 Financial Results
04 Aug 2022 //
PRNEWSWIRE
Theravance Biopharma To Report Second Quarter 2022 Financial Results On August 4, 2022
28 Jul 2022 //
PRESS RELEASE
Theravance Announces Tender Offer For Outstanding 3.25% Convertible Senior Notes
26 Jul 2022 //
PRNEWSWIRE
Theravance, Ultragenyx sell royalties for $1.8B
15 Jul 2022 //
FIERCEPHARMA
Innoviva Sells 15% Stake in Theravance Respiratory Co. to Royalty Pharma
13 Jul 2022 //
BUSINESSWIRE
Theravance Biopharma to Sell TRELEGY ELLIPTA Royalty Interests to Royalty Pharma
13 Jul 2022 //
PRNEWSWIRE
Theravance Biopharma Reports First Quarter 2022 Financial Results
05 May 2022 //
PRNEWSWIRE
Phase 3 rare disease failure extends Theravance`s losing streak
06 Apr 2022 //
FIERCEBIOTECH
Theravance Biopharma hypotension drug fails to meet primary goal
04 Apr 2022 //
REUTERS
Theravance Biopharma to Participate in an Upcoming Investor Conference
22 Feb 2022 //
PRNEWSWIRE
Theravance Biopharma to Report Q4 and FY 2021 Financial Results on Feb 23
09 Feb 2022 //
PRNEWSWIRE
Theravance Biopharma to Participate in an Upcoming Investor Conference
02 Feb 2022 //
PRNEWSWIRE
Theravance Biopharma Enrolls First Patient in YUPELRI Phase 4 Study
10 Jan 2022 //
PRNEWSWIRE
Back-to-back pivotal failures force Theravance to lay off 270 staffers
16 Sep 2021 //
ENDPTS
Theravance Bio suffers double downgrade at JP Morgan after trial setback
15 Sep 2021 //
SEEKINGALPHA
Theravance to lay off 75% of employees alongside larger restructuring
15 Sep 2021 //
BIOPHARMADIVE
Theravance, J&J`s phase 2b ulcerative colitis trial fails
24 Aug 2021 //
ENDPTS
Theravance Biopharma, Inc. Announces Proposed Public Offering of Ordinary Shares
26 Jun 2021 //
PR NEWSWIRE
Theravance Biopharma, Inc. Announces Pricing of Public Offering
26 Jun 2021 //
PR NEWSWIRE
Theravance Biopharma, Inc. Announces Proposed Public Offering of Ordinary Shares
26 Jun 2021 //
PR NEWSWIRE
Theravance Biopharma, Inc. Announces Pricing of Public Offering
26 Jun 2021 //
PR NEWSWIRE
Theravance’s nezulcitinib fails to meet Phase II goals in Covid-19
21 Jun 2021 //
CLINICAL TRAILS ARENA
Theravance Biopharma Report Top-Line Results From Phase 2 Study of Nezulcitinib
21 Jun 2021 //
PRNEWSWIRE
